首页 News 正文

On January 2, 2024, Baekje Shenzhou announced its PD-1 inhibitor Baekzeon& Reg; The new indication of (tirizizumab) has been approved by the National Medical Products Administration (NMPA) of China for first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC) patients. At this point, 12 indications for tirizizumab have been approved in China.
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

海角七号 注册会员
  • 粉丝

    0

  • 关注

    1

  • 主题

    29